Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 13/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.48 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Azd3965 SCHEMBL5093552 | 1.00 | SLC16A1 (0.48) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL14077694 | 0.91 | SLC16A1 (0.57) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| Azd3965 SCHEMBL29127799 | 0.89 | SLC16A1 (0.47) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL23958358 | 0.85 | SLC16A1 (0.57) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5139201 | 0.83 | SLC16A1 (0.45) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5093405 | 0.83 | SLC16A1 (0.41) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5099894 | 0.83 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5093462 | 0.81 | SLC16A1 (0.73) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5138856 | 0.79 | SLC16A1 (0.59) | SLC16A1CYP2C9CYP3A4SLC16A3 | |
| SCHEMBL5093575 | 0.79 | SLC16A1 (0.59) | SLC16A1CYP2C9CYP3A4SLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122005836-A | Targeted mitochondrial lactate nano-drug compound, preparation method and application thereof | 南京鼓楼医院 | 2026-05-12 | — | — | CN | claimed |
| US-12491187-B2 | Use of MCT1 inhibitors to enhance insulin sensitivity | H. LEE MOFFIT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2025-12-09 | — | — | US | claimed |
| EP-4637832-A1 | CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG | Tubulis GmbH (DE) | 2025-10-29 | — | — | EP | claimed |
| EP-4608430-A1 | TREATMENT OF PROSTATE CANCER BY PROMOTING PDE4D7 | Koninklijke Philips N.V. (NL) | 2025-09-03 | — | — | EP | claimed |
| EP-4598516-A2 | MITOCHONDRIA-TARGETED N-ACETYLCYSTEINE AND ANALOGS | The Medical College of Wisconsin, Inc. (US) | 2025-08-13 | — | — | EP | claimed |
| WO-2025151075-A1 | METHODS OF TREATING CANCER AND COMBINATIONS THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-07-17 | — | — | WO | claimed |
| CN-120078720-A | Acid-sensitive liposome for co-regulating and controlling acidic tumor microenvironment and immune checkpoint, and preparation method and application thereof | 浙江工业大学 | 2025-06-03 | — | — | CN | claimed |
| US-20250073321-A1 | Modulation of Oxidative Stress and Amino Acid Metabolism for the Treatment or Prevention of Diseases and Disorders | UNIV NEW YORK (US) | 2025-03-06 | — | — | US | claimed |
| EP-4444319-A1 | CITRIC ACID CYCLE AND LACTATE TRANSPORT INHIBITORS FOR PREVENTION AND/OR TREATMENT OF SKIN DISORDERS | Institute for Stem Cell Science and Regenerative Medicine (Instem) (IN) | 2024-10-16 | — | — | EP | claimed |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | DBCC RES LLC (US) | 2024-09-26 | — | — | US | claimed |
| WO-2023105482-A1 | CITRIC ACID CYCLE AND LACTATE TRANSPORT INHIBITORS FOR PREVENTION AND/OR TREATMENT OF SKIN DISORDERS | INSTITUTE FOR STEM CELL SCIENCE AND REGENERATIVE MEDICINE (INSTEM) (IN) | 2023-06-15 | — | — | WO | claimed |
| CN-113842389-B | Pharmaceutical composition for preventing and/or treating cardiovascular diseases | 忻佑康医药科技(南京)有限公司 | 2022-12-02 | — | — | CN | claimed |
| WO-2022164901-A1 | ENHANCED ANTI-PROLIFERATIVE AND ANTITUMOR IMMUNE EFFECTS OF MITOCHONDRIA-TARGETED HYDROXYUREA | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2022-08-04 | — | — | WO | claimed |
| WO-2022135278-A1 | NOVEL APPLICATION OF AZD3965 MEDICINE | 忻佑康医药科技(南京)有限公司 | 2022-06-30 | — | — | WO | claimed |
| CN-112516147-B | Novel pharmaceutical application of AZD3965 | 忻佑康医药科技(南京)有限公司 | 2022-04-08 | — | — | CN | claimed |
| US-20220098674-A1 | METHODS AND COMPOSITIONS FOR SELECTING A CANCER TREATMENT IN A SUBJECT SUFFERING FROM CANCER | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE - CNRS - (FR) | 2022-03-31 | — | — | US | claimed |
| WO-2010089580-A1 | USE OF A MCT1 INHIBITOR IN THE TREATMENT OF CANCERS EXPRESSING MCT1 OVER MCT4 | ASTRAZENECA AB (SE) | 2010-08-12 | — | — | WO | claimed |
| US-7384951-B2 | Thienopyrimidinediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2008-06-10 | — | — | US | claimed |
| EP-1587812-B1 | THIENOPYRIMIDINEDIONES AND THEIR USE IN THE MODULATION OF AUTOIMMUNE DISEASE | ASTRAZENECA AB (SE) | 2006-08-09 | — | — | EP | claimed |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | ASTRAZENECA AB (SE) | 2006-03-09 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12491187-B2 | Use of MCT1 inhibitors to enhance insulin sensitivity | SLC2A1, SLC2A2, SLC16A1 | SLC16A1 3/4885CYP2C9 4126/4885CYP3A4 2605/4885 |
| US-20060052400-A1 | Thienopyriminediones and their use in the modulation of autoimmune disease | C5, HRH4, CYP2S1 | SLC16A1 4250/4885CYP2C9 113/4885CYP3A4 77/4885 |
| US-20240316055-A1 | METHODS FOR TREATING LEIGH SYNDROME | ECHS1, GLS2, OAT | SLC16A1 908/4885CYP2C9 2786/4885CYP3A4 2981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.